Pipeline

In order to demonstrate the diversity of the AMR-dedicated SMEs’ pipeline in Europe, the BEAM Alliance has collated its members’ technological assets into a comprehensive portfolio. While its size is already impressive, the proposed categorization approach is further revealing the high level of innovativeness that is being deployed, both at clinical and preclinical stages.

BEAM Infection Curve (BIC)

BEAM Infection Curve (BIC)

Pipeline Rx

Click on column headers to sort the table

memberproductbic*typetargets/indicationsdevelopment
stage
NovaBiotics LtdNP339Protein/Peptide Aspergillus spp, Candida spp, Mucorales, Candida auris/Prophylaxis and treatment of fungal diseasePre-clinical
NovaBiotics LtdNM002-IVOtherBroad-spectrum G+/G-/Community acquired pneumonia (CAP)Phase III
VibioSphenTherapeptics3aProtein/PeptideA. baumannii; P. aeruginosa; Klebsiella pneumoniae; Staphylococcus aureus; Clostridioides difficile/Intra-abdominal infections (cIAI)Lead opt
Summit Therapeutics plcDDS-01 Series3aNMENeisseria gonorrhoeae/GonorrhoeaLead opt
Mileutis Ltd.Peptide(s) hydrolyzed from caseinProtein/PeptideP. aeruginosa; Enterobacter spp.; Salmonella sppPre-clinical
Helperby Therapeutics LtdHY-007 Infusion3d/5aOtherAcinetobacter baumannii/Lung, blood. CNS and skin/soft tissue structure infectionsLead opt
Helperby Therapeutics LtdHY-001 Infusion3d/5aOtherEscherichia coli, Klebsiella spp/Intra-abdominal infections Phase I
NovaBiotics LtdNP4323aProtein/PeptideA. baumannii; P. aeruginosa; Enterobacter spp.; Clostridioides difficilePre-clinical
NovaBiotics LtdNP1081bProtein/PeptideStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniaePre-clinical
Phico Therapeutics LtdSASPject™ PT93aPhageS. aureus/Animal HealthLead opt
Phico Therapeutics LtdSASPject™ PT83aPhageS. aureus/BacteraemiaLead opt
Phico Therapeutics LtdSASPject™ PT3.93aPhageP. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
Nabriva Therapeutics GmbHNext Generation Pleuromutilins3dNMEResistant Gram-positive and Gram-negative bacterial organisms/Community acquired pneumonia (CAP) and ABSSSILead opt
Nabriva Therapeutics GmbHLefamulin3aNMEStaphylococcus aureus; Haemophilus influenzae/Bacterial exacerbations in patients with cystic fibrosisPhase I
Nabriva Therapeutics GmbHLefamulin3aNMENeisseria gonorrhoea; Mycoplasma genitalium; Chlamydia trachomatis/Sexually transmitted infections (STI)Phase I
Da VolterraDAV3614bOtherA. baumannii; P. aeruginosa; Enterobacter spp.; Enterococcus faecium; Clostridioides difficile / Prevention of colonization by resistant bacteria and subsequent infections in patients hospitalized in ICUsLead opt
BasileaNovel target (IspF inhibitor)3aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Discovery
BasileaNovel target (DXR inhibitor)3aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BasileaNovel class3aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BasileaNovel class3aNMEAspergillus spp; Mucorales; Fusarium spp; Scedosporium spp; Cryptococcus spp; Candida spp / Invasive fungal diseaseLead opt
Destiny Pharma plcXF-731bNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of oral mucositisPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / BurnsPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Treatment of chronic rhinosinusitisPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Cystic fibrosis associated infectionsPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of post-surgical infectionPhase II
Destiny Pharma plcNTCD-M31bNMEToxigenic strains of C. difficile / Prevention of recurrence of C diff infectionPhase II
Destiny Pharma plcSPOR-COV1aNMERespiratory viruses, SARS-COV-2 & Influenza / Prevention of viral respiratory infectionsPre-clinical
Infex Therapeutics LtdRESP-X3cAntibodyP. aeruginosa / Non-cystic-fibrosis bronchiectasisPhase I
Infex Therapeutics LtdMET-X3dNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp. / Complicated urinary tract infections (cUTI), HAP, VAP, bloodstream infections, intra-abdominal infectionsPre-clinical
Infex Therapeutics LtdCOV-X-OtherPan-coronavirus / Coronavirus infectionsLead opt
Infex Therapeutics LtdRDX-023aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp. / Gram-negative AMR infectionsDiscovery
Infex Therapeutics LtdPAN-X-OtherPan-coronavirus / Coronavirus infectionsDiscovery
AdjuTec Pharma ASAPC2473dNMEEscherichia coli; Klebsiella pneumoniae / complicated urinary tract infections (cUTI)Pre-clinical
Ultupharma ABULT23aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Salmonella spp; Shigella spp.; Helicobacter pylori; Haemophilus influenzae; Staphylococcus aureus; Streptococcus pneumoniae / Bloodstream infectionsPre-clinical
Ultupharma ABULT33aProtein/PeptideA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Staphylococcus aureus / Bloodstream infectionsLead opt
VAXDYNKapaVax1aVaccineKlebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii/Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Pre-clinical
Spexis AGLptA-OMPTA3aProtein/PeptideEscherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp. / HABP/VABP, cUTI, cIAILead opt
F2G LtdOlorofim3aNMEDHODH inhibitor/Aspergillosis refractory, resistant or intolerant; Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species; Coccidioidomycosis refractoryPhase III
AdjuTec Pharma ASAPC1483dNMEKlebsiella pneumoniae; Enterobacter spp / complicated urinary tract infections (cUTI)IND/CTA ready
Diotheris SASDECOLONIZE1bOtherS. aureus/Decolonization of multi-resistant S. aureusDiscovery
Diotheris SASPREVENT1bOtherS. aureus/Prevent infection by multi-resistant S. aureusPre-clinical
Aptorum Group LtdALS-33dOtherStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae//Treatment of gram+ve bacterial infectionsLead opt
Aptorum Group LtdALS-24aOtherStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae/Treatment of gram+ve bacterial infectionsLead opt
Aptorum Group LtdALS-13aOtherInfluenza virus A//Treatment of viral infectionsLead opt
Aptorum Group LtdALS-43cOtherS. aureus//Treatment of bacterial infectionsPhase I
Debiopharm InternationalDebio 1454/S3aNMEA. baumannii/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
OLGRAMOl20-015aProtein/PeptideP. aeruginosa; Broad-spectrum G+/G-/Cystic fibrosis associated infectionsPre-clinical
Selmod GmbHslm 5003aNMEEscherichia coli; Broad-spectrum G+/G-/Complicated urinary tract infections (cUTI)Pre-clinical
Selmod GmbHslm 4003aNMEA. baumannii; Broad-spectrum G+/G-/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
Selmod GmbHslm 3003aNMEKlebsiella pneumoniae; Broad-spectrum G+/G-/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
Selmod GmbHslm 2003aProtein/PeptideCandida albicans, Aspergillus fumigatus, Candida auris/Invasive aspergillosis, Oral Candidiasis, Bronchopulmonary aspergillosisLead opt
Selmod GmbHslm 1003aNMECandida albicans, Aspergillus fumigatus, Candida auris/Invasive aspergillosis, Oral Candidiasis, Bronchopulmonary aspergillosisLead opt
BioNTech R&DPM-4773aProtein/PeptideGardnerella/Bacterial vaginosisPre-clinical
Nabriva Therapeutics GmbHBC-21263aNMEA. baumannii; P. aeruginosa; Enterobacterales/Hospital-acquired or Ventilator-acquired bacterial pneumonia (HABP/VABP)Pre-clinical
Nabriva Therapeutics GmbHBC-70133aNMEStaphylococcus aureus; ß-hemolytic Streptococcus spp.; coagulase-negative Staphylococcus spp./Topical treatment of skin and skin structure infectionsPhase I
AiCuris Anti-infective Cures AGNPI Scaffolds3aNMEUndisclosed/Healthcare-asscoiated infectionsLead opt
AiCuris Anti-infective Cures AGMacrocyles3aNMEUndisclosedLead opt
Pherecydes PharmaPP9703aPhageEscherichia coli/Complicated urinary tract infections (cUTI)Pre-clinical
Pherecydes PharmaPP9543aPhageEscherichia coli/Complicated urinary tract infections (cUTI)Pre-clinical
Pherecydes PharmaPP8143aPhageEscherichia coli/Complicated urinary tract infections (cUTI)Pre-clinical
Pherecydes PharmaPP7003aPhageEscherichia coli/Complicated urinary tract infections (cUTI)Pre-clinical
Assuré Medical LimitedSol-UTI1bOtherP. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Proteus spp.; Staphylococcus aureus / Uncomplicated urinary tract infections (uUTI)Pre-clinical
BioVersys AGBV1003aNMEA. baumannii/HAP, VAP, BSIPhase I
Madam Therapeutics BVP103aProtein/PeptideA. baumannii/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
AlphanososW5P1 + WXPYY (more potent lead)OtherN. gonorrhoeae; S. aureus/GonorrhoeaIND/CTA ready
ABAC therapeuticsABAC-402443aNMEStaphylococcus aureus/Hospital infectionsLead opt
ABAC therapeuticsABAC-404113aNMEStreptococcus pneumoniae/Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Lead opt
ANTABIO S.A.SSBLi (ANT3310)3dNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) IND/CTA ready
VibioSphenSativa3bNMEP. aeruginosaPre-clinical
VAXDYNAcinetoVax1aVaccineAcinetobacter baumannii/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
Summit Therapeutics plcSMT0267383aNMEEscherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp./Complicated urinary tract infections (cUTI)Pre-clinical
Summit Therapeutics plcRidinilazole3aNMEC. difficile infectionsPhase III
QureTech Bio ABTIB3aNMEC. trachomatis / Ocular Chlamydia infectionLead opt
QureTech Bio ABGmP3dNMEStaphylococcus aureus; Enterococcus faecium; Clostridioides difficile; E. faecalis; S. epidermidis / Complicated urinary tract infections (cUTI)Lead opt
QureTech Bio ABCIB3aNMEC. trachomatis / Genital Chlamydia infectionLead opt
QureTech Bio ABMTI3dNMEMycobacterium tuberculosis / TuberculosisLead opt
Spexis AGMurepavadin (inhaled)3aProtein/PeptideP. aeruginosa / Cystic fibrosis associated infectionsPhase I
Spexis AGColiFin®3aProtein/PeptideA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae / Cystic fibrosis associated infectionsPhase III
Pherecydes PharmaPN17773aPhageP. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)IND/CTA ready
Pherecydes PharmaPN17923aPhageP. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)IND/CTA ready
Pherecydes PharmaPN17973aPhageP. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)IND/CTA ready
Pherecydes PharmaPN14933aPhageStaphylococcus aureus/Prosthetic Joint infections (PJI)IND/CTA ready
Pherecydes PharmaPN18153aPhageStaphylococcus aureus/Prosthetic Joint infections (PJI)IND/CTA ready
Pherecydes PharmaPN14503aPhageP. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)IND/CTA ready
Omnix MedicalOMN63a/5aProtein/PeptideA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Phase I
NovaBiotics LtdNM001 inhaled Lynovex®1bOtherBroad-spectrum G+/G-/Cystic fibrosis associated infectionsIND/CTA ready
NovaBiotics LtdNM001 oral Lynovex®3dOtherBroad-spectrum G+/G-/Cystic fibrosis associated infectionsPhase II
NosopharmNOSO-2G3aNME A. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
NosopharmNOSO-5023aNME Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Staphylococcus aureus/Complicated urinary tract infections (cUTI)IND/CTA ready
Northern Antibiotics Oy (Ltd)NAB8153aProtein/PeptideA. baumannii; Enterobacter spp./Complicated urinary tract infections (cUTI)Lead opt
Northern Antibiotics Oy (Ltd)NAB7393aProtein/PeptideA. baumannii; Enterobacter spp./Complicated urinary tract infections (cUTI)Lead opt
Nabriva Therapeutics GmbHLefamulin3aNMEHaemophilus influenzae; Staphylococcus aureus; Streptococcus pneumoniae; Legionella pneumophila; Mycoplasma pneumoniae; Chlamydophila pneumoniae; beta-hemolytic Streptococcus spp.; Viridans group Streptococcus spp.; Staphylococcus spp./CAP and URTI in pediatric patientsPhase I
Nabriva Therapeutics GmbHLefamulin3aNMEStaphylococcus aureus; beta-hemolytic Streptococcus spp.; Viridans group Streptococcus spp.; Staphylococcus spp./Acute bacterial skin and skin structure infections (ABSSSI)Phase II
Nabriva Therapeutics GmbHLefamulin3aNMEHaemophilus influenzae; Staphylococcus aureus; Streptococcus pneumoniae; Legionella pneumophila; Mycoplasma pneumoniae; Chlamydophila pneumoniae; beta-hemolytic Streptococcus spp.; Viridans group Streptococcus spp.; Staphylococcus spp./Community acquired pneumonia (CAP) Marketed
Mutabilis SAS2G-Dabocin3aNMEEnterobacterales, P. aeruginosa, A. baumannii/Complicated urinary tract infections (cUTI)Lead opt
Mutabilis SASEBL-14633aNMEEnterobacterales/Complicated urinary tract infections (cUTI)Pre-clinical
Madam Therapeutics BVSAAP-1483aProtein/PeptideBroad-spectrum G+/G-/Complicated urinary tract infections (cUTI)Lead opt
IMMUNETHEP, SAUnimab3cAntibodyEscherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; Streptococcus pneumoniae; S. agalactiae/Bloodstream infectionsPre-clinical
IMMUNETHEP, SAPNV1aVaccineS. aureus, E. Coli, ETEC/Bloodstream infections, Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Pre-clinical
Hypharm GmbHHY-1331bPhageStaphylococcus aureus/Nasal colonization with MRSAIND/CTA ready
Helperby Therapeutics LtdHY-001 Infusion3d/5aOtherEscherichia coli, Klebsiella spp/Complicated urinary tract infections (cUTI)Phase II
Helperby Therapeutics LtdHY-003 Infusion3d/5aOtherEscherichia coli, Klebsiella spp/Skin/soft tissue structure, lung, blood and CNS infectionsPre-clinical
Helperby Therapeutics LtdHY-004 Inhalation3d/5a/1dOtherP. aeruginosa; Staphylococcus aureus including MRSA/Cystic fibrosis associated infectionsPre-clinical
Helperby Therapeutics LtdHY-005 Infusion3d/5aOtherP. aeruginosa; Staphylococcus aureus including MRSA/Lung, blood. CNS and skin/soft tissue structure infectionsLead opt
Eligo BioscienceEB0041bPhageEscherichia coli; Klebsiella pneumoniae/Bloodstream infectionsPre-clinical
DEINOVEDNV38373aNMEC. difficile infectionsPhase II
Debiopharm InternationalDebio 14533aNMENeisseria gonorrhoeae; C. trachomatis/GonorrhoeaPre-clinical
Debiopharm InternationalAfabicin (Debio 1450)3aNMEABSSI (caused by S. aureus), osteomyelitisPhase II
Combioxin SACAL024aOtherVirulence factors, broad spectrum Gram+ and Gram-, resistance agnostic/Severe community-acquired bacterial pneumoniaPhase II
Centauri Therapeutics LtdABX013cOtherA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp./Healthcare-asscoiated infectionsPre-clinical
Centauri Therapeutics LtdABX023cOtherP. aeruginosa/Healthcare-asscoiated infectionsPre-clinical
BioVersys AGBV2004aNMEStaphylococcus aureus/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BioVersys AGBV3003aNMEA. baumannii; P. aeruginosa; Enterobacter spp.; Staphylococcus aureus; Enterococcus faecium/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BioVersys AGBVL-GSK0983dNMEM. tuberculosis/TuberculosisPhase I
BioFilm PharmaBFP0023eNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; Enterococcus faecium/Cystic fibrosis associated infectionsLead opt
BioFilm PharmaBFP1013eNMEStaphylococcus aureus/Local-Diabetic Foot UlcerLead opt
BioFilm PharmaBFP1023eNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; Enterococcus faecium/Cystic fibrosis associated infectionsLead opt
BioFilm PharmaBFP0013eNMEStaphylococcus aureus/Local - Diabetic Foot UlcerLead opt
BasileaCeftobiprole3aNMES. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa / Staphylococcus aureus bacteremia; Acute bacterial skin and skin structure infectionsPhase III
BasileaCeftobiprole3aNMES. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa; Haemophilus influenzae / CAP, HAPMarketed
ANTABIO S.A.SPEi (ANT3273)3c/1b/4a/4bNMEP. aeruginosa / Non-CF bronchiectasis associated infectionsPre-clinical
ANTABIO S.A.SMBLi (ANT2681)3dNMEEscherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Complicated urinary tract infections (cUTI)IND/CTA ready
AlphanososW16P05763eOtherA. baumannii, P. aeruginosa, MRSA,N. gonorrhoeae, M. tuberculosis/Infectious skin conditions (eczema, acne, sporiasis, ...), difficult woundsPre-clinical
ALLECRA THERAPEUTICSCefepime / Enmetazobactam3dNMEcUTI, APPhase III
AktheliaAKT-0113cNMEEscherichia coli; Salmonella spp; Broad-spectrum G+/G-/GI infectionsLead opt
AiCuris Anti-infective Cures AGArtilysins3aProtein/PeptideUndisclosed/Bloodstream infections, Diabetic foot infectionLead opt
AGILeBiotics B.V.ABX-3953aNMEHospital-treated MDR Gram-negative infectionsLead opt
AGILeBiotics B.V.ABX-605 (Maranmicin)3aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Staphylococcus aureus; Enterococcus faecium; Mycobacterium Avium Complex; Mycobacterium Abscessus/Cystic fibrosis associated infections - NTMPre-clinical
ABAC therapeuticsABAC-398773aNMEA. baumannii/Hospital infectionsPre-clinical
Da VolterraDAV1324bOtherPrevention of C.difficile infectionsPhase II
PreviousPage 1/13show allNext

*BIC: BEAM Infection Curve

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

Pipeline Dx

Click on column headers to sort the table

memberkit/testtargeted resultpathogens/indicationslab workflowdevelopment stage
NG BiotechNG-Test Blood Culture PrepAMR Mechanism of Resistance IDEnterobacteriaceae /
Rapid and Direct detection of the major groups of carbapenemases
From isolated colony
LFIA
<30 minutes
CE-IVD and/or FDA 510k
NG BiotechNG-Test MCR-1AMR Mechanism of Resistance IDEnterobacteriaceae /
Detection of colistine resistance
From isolated colony
LFIA
<30 minutes
CE-IVD and/or FDA 510k
NG BiotechNG-Test CTX-M MULTIAMR Mechanism of Resistance IDEnterobacteriaceae /
Detection of the 5 most prevalent ESBL CTX-M Groups (1, 2, 8, 9 and 25)
From isolated colony
LFIA
<30 minutes
CE-IVD and/or FDA 510k
NG BiotechNG-Test CARBA 5AMR Mechanism of Resistance IDEnterobacteriaceae, carbapenem-resistant; 3rd generation cephalosporin-resistant; A. baumannii, carbapenem-resistant; P. aeruginosa, carbapenem-resistant /
Detection and differentiation of KPC, OXA-48, VIM, IMP and NDM
From PBS + Isolated colony
LFIA
<30 minutes
CE-IVD and/or FDA 510k
MeMed Diagnostics Ltd.MeMed COVID-19 Severity™Likelihood of meeting severe outcomePoint-of-need aid to the clinician's stratification of COVID-19 disease severityFrom serum/plasma
 
<30 minutes
CE-IVD and/or FDA 510k
BioFilm ControlAntiBiofilmogram Urinary CareAST PhenotypingE. coli /
Urinary Tract Infections, Catheter Associated Urinary Tract Infections
From isolated colony
Microplate-reader
<4h
Development Phase
BioFilm ControlAntiBiofilmogram Lung CareAST PhenotypingPseudomonas aeruginosa /
Cystic Fibrosis
From isolated colony
Microplate-reader
<4h
Prototype in Lab
BioFilm ControlAntiBiofilmogram Lung CareAST PhenotypingStaphylococcus aureus /
Cystic Fibrosis
From isolated colony
Microplate-reader
<4h
Prototype in Lab
BioFilm ControlAntiBiofilmogram Wound CareAST PhenotypingStaphylococcus aureus /
Diabetic Foot Ulcer, Joint & Bone Infections
From isolated colony
Microplate-reader
<4h
CE-IVD and/or FDA 510k
MeMed Diagnostics Ltd.MeMed BV®Viral vs BacterialPoint-of-need aid to the clinician's discrimination of the viral/bacterial nature of an infectionFrom serum/plasma
 
<30 minutes
CE-IVD and/or FDA 510k
PreviousPage 1/1Next

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.